Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lyell Immunopharma, Inc. - Common Stock (NQ: LYEL )

0.5938 -0.0102 (-1.69%)
Streaming Delayed Price Updated: 12:50 PM EST, Jan 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lyell Immunopharma, Inc. - Common Stock

< Previous 1 2 Next >
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces Participation in September Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces Participation in March Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing
Six presentations highlight innovations designed to shorten TIL manufacturing, new nonclinical data on LYL119, new technologies and clinical trials in progress 
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials in progress 
From Lyell Immunopharma, Inc
Via GlobeNewswire
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
From Lyell Immunopharma, Inc; Cellares
Via GlobeNewswire
Lyell Immunopharma to Participate in Upcoming Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Participate in BofA Securities Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
From Lyell Immunopharma, Inc
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.